Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA

https://doi.org/10.1016/j.clinbiochem.2007.11.010Get rights and content

Abstract

Objectives

To develop an assay for the determination of ZAG in human serum, and to investigate its clinical relevance as a marker of metabolic syndrome.

Design and methods

A new sandwich ELISA was introduced and clinically tested.

Results

ZAG serum level did not differentiate healthy subjects (27.4 ± 8.3 mg/L; N = 132) from patients with metabolic syndrome (24.9 ± 8.1; N = 92). ZAG correlated with glucose, creatinine and uric acid.

Conclusion

The immunoassay offers a new research tool for glucose metabolism.

Keywords

Zinc-alpha-2-glycoprotein
ELISA
Metabolic syndrome
Obesity

Cited by (0)

View Abstract